Poseida Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting

Preclinical data to be presented supports potential of anti-c-kit CAR-T cells as a highly specific and less toxic conditioning regimen for hematopoietic stem cell transplantation SAN DIEGO, May 2, 2022 /PRNewswire/ — Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage…

Click here to view original post